IRWD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
133.0M
+17.7%
113.0M
+6.1%
106.5M
+123.2%
47.7M
-60.9%
122.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
133.0M
+17.7%
113.0M
+6.1%
106.5M
+123.2%
47.7M
-60.9%
122.1M
Operating Expenses
39.9M
+18.3%
33.7M
-0.6%
33.9M
-17.0%
40.9M
-12.2%
46.6M
R&D
28.4M
+26.5%
22.4M
+2.2%
21.9M
+0.4%
21.9M
-2.7%
22.5M
SG&A
11.6M
+2.1%
11.3M
-6.0%
12.0M
-37.6%
19.3M
-11.9%
21.9M
Operating Income
93.1M
+17.4%
79.3M
+9.3%
72.6M
+966.5%
6.8M
-91.0%
75.5M
EBITDA
93.6M
+17.3%
79.8M
+9.3%
73.0M
+940.6%
7.0M
-91.0%
78.2M
Net Income
59.8M
+16.7%
51.3M
+25.8%
40.8M
+1891.4%
-2276000
-105.7%
40.1M
EPS (Basic)
$0.36
+16.1%
$0.31
+24.0%
$0.25
+2600.0%
$-0.01
-104.0%
$0.25
EPS (Diluted)
$0.36
+16.1%
$0.31
+29.2%
$0.24
+1300.0%
$-0.02
-108.7%
$0.23
Shares (Diluted)
168.2M
+0.6%
167.2M
+0.3%
166.7M
+22.2%
136.4M
-23.3%
177.8M
Ironwood Pharmaceuticals, Inc. - (IRWD) — Financials